Syngene International (BOM:539268) ROCE % : 17.73% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Syngene International ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Syngene International's annualized ROCE % for the quarter that ended in Mar. 2024 was 17.73%.

Syngene International ROCE % Historical Data

The historical data trend for Syngene International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syngene International ROCE % Chart

Syngene International Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

21.22

15.59

12.42

14.23

13.84

Syngene International Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															20.79	11.49	14.17	12.90	17.73

Syngene International ROCE % Calculation

Syngene International's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	6680	/	( ( (58310 - 11882)	+	(61516 - 11443) )	/ 2 )
	=	6680	/	( (46428	+	50073)	/ 2 )
	=	6680	/	48250.5
	=	13.84 %

Syngene International's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	8876	/	( ( (0 - 0)	+	(61516 - 11443) )	/ 1 )
	=	8876	/	( ( 0	+	50073 )	/ 1 )
	=	8876	/	50073
	=	17.73 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Syngene International (BOM:539268) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Syngene International ROCE % Related Terms

Thank you for viewing the detailed overview of Syngene International's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Syngene International (BOM:539268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syngene International Ltd (BOM:539268) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SYNGENE:India

Address

Jigani Link Road, Biocon SEZ, Biocon Park, Plot No. 2 and 3, IV Phase, Bommasandra Industrial Area, Bangalore, KA, IND, 560 099

Website

https://www.syngeneintl.com

Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the US. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.

Syngene International (BOM:539268) Headlines

No Headlines